Elmed Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.20 Cr
as on 24-10-2024
- Paid Up Capital ₹ 2.20 Cr
as on 24-10-2024
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.26 Cr
as on 24-10-2024
- Revenue 82.80%
(FY 2023)
- Profit 775.65%
(FY 2023)
- Ebitda 59.94%
(FY 2023)
- Net Worth 24.59%
(FY 2023)
- Total Assets 18.86%
(FY 2023)
About Elmed Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.20 Cr and a paid-up capital of Rs 2.20 Cr.
The company currently has active open charges totaling ₹10.26 Cr.
Pruthivin Madduri and Nikhil Konkathi serve as directors at the Company.
- CIN/LLPIN
U24230TG2018PTC129033
- Company No.
129033
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Dec 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Elmed Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pruthivin Madduri  | Managing Director | 13-Dec-2018 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nikhil Konkathi | Director | 13-Dec-2018 | Current |
Financial Performance of Elmed Life Sciences.
Elmed Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 82.8% increase. The company also saw a substantial improvement in profitability, with a 775.65% increase in profit. The company's net worth Soared by an impressive increase of 24.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elmed Life Sciences?
In 2023, Elmed Life Sciences had a public holding of 27.27%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Anura Theraputics Private LimitedActive 6 years 30 daysPruthivin Madduri and Nikhil Konkathi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 08 Dec 2022 | ₹1.71 M | Open |
Indian Bank Creation Date: 07 Jul 2020 | ₹6.09 Cr | Open |
Indian Bank Creation Date: 22 Jan 2020 | ₹4.00 Cr | Open |
How Many Employees Work at Elmed Life Sciences?
Elmed Life Sciences has a workforce of 26 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elmed Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elmed Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
